Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Silence Therapeutics sells another slug of its holding in Arrowhead

In total, Silence Therapeutics has now sold 6,358,850 Arrowhead shares on the open market, realising proceeds of US$23.0mln (£17.2mln)
Silence Therapeutics sells another slug of its holding in Arrowhead
The company will use the proceeds from the sale to fund working capital requirements

Silence Therapeutics plc (LON:SLN) said it has sold 2,317,693 shares in Arrowhead Pharmaceuticals Inc.(NASDAQ:ARWR) for an average price of US$3.60, reducing its holding in Arrowhead to 0.63%.

In total, Silence Therapeutics has now sold 6,358,850 Arrowhead shares on the open market, realising proceeds of US$23.0mln (£17.2mln). The average purchase price per share was US$1.65 and the average selling price of the 6,358,850 shares sold was US$3.62. The total profit recorded is therefore US$12.5mln, or £8.7mln.

READ: Silence Therapeutics offloads a slug of its Arrowhead holding at significant profit

The company will use the proceeds from the sale to fund working capital requirements.

Silence said it has determined that it may be advantageous to liquidate portions or all of its remaining holding of Arrowhead shares from time to time in an orderly manner consistent with prudent management of its investment.

READ: Silence Therapeutics' value climbs as it looks for IP redress

The Company still holds 472,509 common shares which represents 0.63% of Arrowhead.

 

View full SLN profile View Profile

Silence Therapeutics plc Timeline

Related Articles

Once the phase III trial is completed, Futura plans to either sell off the asset or find a partner
September 26 2018
The pharma group expects to dose the first patient in the Phase III trial of its MED2002 erectile dysfunction treatment within the next month
scientist in lab
September 25 2018
VAL401 is ValiRx’s most advanced compound, with earlier trial results suggesting it can improve quality of life and chances of survival of lung cancer patients
scientist in lab
September 07 2018
Normally, patients have to wait until regulators have approved a drug before they get access to it, but up to 500 lupus sufferers will receive Lupuzor as part of a Managed Access Programme

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use